Inactivation induced by pathogenic Cav1.3 L-type Ca2+-channel variants enhances sensitivity for dihydropyridine Ca2+ channel blockers.

IF 6.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Ferenc Török, Sarah Salamon, Nadine J Ortner, Monica L Fernández-Quintero, Jan Matthes, Jörg Striessnig
{"title":"Inactivation induced by pathogenic Ca<sub>v</sub>1.3 L-type Ca<sup>2+</sup>-channel variants enhances sensitivity for dihydropyridine Ca<sup>2+</sup> channel blockers.","authors":"Ferenc Török, Sarah Salamon, Nadine J Ortner, Monica L Fernández-Quintero, Jan Matthes, Jörg Striessnig","doi":"10.1111/bph.17357","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Pathogenic gain-of-function mutations in Ca<sub>v</sub>1.3 L-type voltage-gated Ca<sup>2+</sup>-channels (CACNA1D) cause neurodevelopmental disorders with or without endocrine symptoms. We aimed to confirm a pathogenic gain-of function phenotype of CACNA1D de novo missense mutations A749T and L271H, and investigated the molecular mechanism causing their enhanced sensitivity for the Ca<sup>2+</sup>-channel blocker isradipine, a potential therapeutic for affected patients.</p><p><strong>Experimental approach: </strong>Wildtype and mutant channels were expressed in tsA-201 cells and their gating analysed using whole-cell and single-channel patch-clamp recordings. The voltage-dependence of isradipine action was quantified using protocols inducing variable fractions of inactivated channels. The molecular basis for altered channel gating in the mutants was investigated using in silico modelling and molecular dynamics simulations.</p><p><strong>Key results: </strong>Both mutations were confirmed pathogenic due to characteristic shifts of voltage-dependent activation and inactivation towards negative potentials (~20 mV). At negative holding potentials both mutations showed significantly higher isradipine sensitivity compared to wildtype. The affinity for wildtype and mutant channels increased with channel inactivation as predicted by the modulated receptor hypothesis (30- to 40-fold). The IC<sub>50</sub> was indistinguishable for wildtype and mutants when >50% of channels were inactivated.</p><p><strong>Conclusions and implications: </strong>Mutations A749T and L271H induce pathogenic gating changes. Like wildtype, isradipine inhibition is strongly voltage-dependent. Our data explains their apparent higher drug sensitivity at a given negative voltage by the availability of more inactivated channels due to their more negative inactivation voltage range. Low nanomolar isradipine concentrations will only inhibit Ca<sub>v</sub>1.3 channels in neurons during prolonged depolarized states without selectivity for mutant channels.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.17357","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Pathogenic gain-of-function mutations in Cav1.3 L-type voltage-gated Ca2+-channels (CACNA1D) cause neurodevelopmental disorders with or without endocrine symptoms. We aimed to confirm a pathogenic gain-of function phenotype of CACNA1D de novo missense mutations A749T and L271H, and investigated the molecular mechanism causing their enhanced sensitivity for the Ca2+-channel blocker isradipine, a potential therapeutic for affected patients.

Experimental approach: Wildtype and mutant channels were expressed in tsA-201 cells and their gating analysed using whole-cell and single-channel patch-clamp recordings. The voltage-dependence of isradipine action was quantified using protocols inducing variable fractions of inactivated channels. The molecular basis for altered channel gating in the mutants was investigated using in silico modelling and molecular dynamics simulations.

Key results: Both mutations were confirmed pathogenic due to characteristic shifts of voltage-dependent activation and inactivation towards negative potentials (~20 mV). At negative holding potentials both mutations showed significantly higher isradipine sensitivity compared to wildtype. The affinity for wildtype and mutant channels increased with channel inactivation as predicted by the modulated receptor hypothesis (30- to 40-fold). The IC50 was indistinguishable for wildtype and mutants when >50% of channels were inactivated.

Conclusions and implications: Mutations A749T and L271H induce pathogenic gating changes. Like wildtype, isradipine inhibition is strongly voltage-dependent. Our data explains their apparent higher drug sensitivity at a given negative voltage by the availability of more inactivated channels due to their more negative inactivation voltage range. Low nanomolar isradipine concentrations will only inhibit Cav1.3 channels in neurons during prolonged depolarized states without selectivity for mutant channels.

致病性 Cav1.3 L 型 Ca2+ 通道变体引起的失活会增强对二氢吡啶类 Ca2+ 通道阻滞剂的敏感性。
背景和目的:Cav1.3 L型电压门控Ca2+通道(CACNA1D)的致病性功能增益突变会导致伴有或不伴有内分泌症状的神经发育障碍。我们的目的是证实CACNA1D新发错义突变A749T和L271H的致病性功能增益表型,并研究导致它们对Ca2+通道阻滞剂异雷地平敏感性增强的分子机制,异雷地平是受影响患者的一种潜在疗法:实验方法:在tsA-201细胞中表达野生型和突变型通道,并使用全细胞和单通道膜片钳记录分析它们的门控。实验方法:在tsA-201细胞中表达野生型和突变型通道,并利用全细胞和单通道膜片钳记录分析它们的门控,利用诱导不同比例失活通道的方案量化异拉地平作用的电压依赖性。利用硅建模和分子动力学模拟研究了突变体通道门控改变的分子基础:主要结果:由于电压依赖性激活和失活向负电位(约 20 mV)的特征性转移,两种突变均被证实具有致病性。与野生型相比,这两种突变体在负电位时对异雷地平的敏感性明显更高。根据受体调节假说的预测,野生型和突变型通道的亲和力随着通道失活而增加(30 至 40 倍)。当超过 50% 的通道失活时,野生型和突变体的 IC50 无法区分:A749T 和 L271H 突变诱导致病性门控变化。与野生型一样,异雷地平对通道的抑制也具有很强的电压依赖性。我们的数据解释了它们在给定负电压下明显更高的药物敏感性,因为它们的失活电压范围更负,因此有更多的失活通道。低纳摩尔浓度的异拉地平只能在长时间去极化状态下抑制神经元中的 Cav1.3 通道,而对突变通道没有选择性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信